Memorial Sloan Kettering Cancer Center
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Inclusion Criteria: * Non-metastatic prostate cancer. * Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed) * Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT Exclusion Criteria: * None
HDR Brachytherapy
SBRT alone